[HTML][HTML] Enteric coating of tablets containing an amorphous solid dispersion of an enteric polymer and a weakly basic drug: A strategy to enhance in vitro release

HT Nguyen, T Van Duong, LS Taylor - International Journal of …, 2023‏ - Elsevier
Recent work has highlighted that amorphous solid dispersions (ASDs) containing
delamanid (DLM) and an enteric polymer, hypromellose phthalate (HPMCP), appear to be …

Atomic layer coating to inhibit surface crystallization of amorphous pharmaceutical powders

DE Moseson, EG Benson, HT Nguyen… - … Applied Materials & …, 2022‏ - ACS Publications
Preventing crystallization is a primary concern when develo** amorphous drug
formulations. Recently, atomic layer coatings (ALCs) of aluminum oxide demonstrated …

Surface nanocoating of high drug-loading spray-dried amorphous solid dispersions by atomic layer coating: Excellent physical stability under accelerated storage …

T Van Duong, HT Nguyen, F Wang, M Wang… - International Journal of …, 2022‏ - Elsevier
Physical instability remains a major concern with amorphous solid dispersions (ASDs). In
addition to bulk crystallization inhibition, another potential strategy to improve the physical …

Amorphous drug–polymer salt with high stability under tropical conditions and fast dissolution: the case of clofazimine and poly (acrylic acid)

Y Gui, EC McCann, X Yao, Y Li, KJ Jones… - Molecular …, 2021‏ - ACS Publications
We report that the stability of amorphous clofazimine (CFZ) against crystallization is vastly
improved by salt formation with a polymer without sacrificing dissolution rate. A simple slurry …

Amorphous drug–polymer salt with high stability under tropical conditions and fast dissolution: the challenging case of lumefantrine-PAA

X Yao, S Kim, Y Gui, Z Chen, J Yu, KJ Jones… - Journal of Pharmaceutical …, 2021‏ - Elsevier
Abstract Lumefantrine (LMF), a high-mobility and easy-to-crystallize WHO drug for treating
malaria, can form an amorphous salt with poly (acrylic acid)(PAA) that is remarkably stable …

Surface Accelerates Crystal Nucleation: The Case of Molnupiravir

K Sun, P Han, C Yao, Y Zhao, C Zhang… - Crystal Growth & …, 2024‏ - ACS Publications
Molecules at the liquid/vapor interface have different properties, such as faster mobility and
special packing structure, which can potentially affect crystal nucleation. However, the …

Polymorph transformation of solid drugs and inhibiting strategies

Y Feng, H Wang, D Wu, K Chen, N Wang, T Wang… - …, 2024‏ - pubs.rsc.org
Metastable forms and amorphous forms exhibit higher solubility and dissolution rates
compared to stable crystalline forms, making them viable options for pharmaceuticals with …

Surface stabilization and dissolution rate improvement of amorphous compacts with thin polymer coatings: can we have it all?

D Novakovic, L Peltonen, A Isomäki… - Molecular …, 2020‏ - ACS Publications
The distinction between surface and bulk crystallization of amorphous pharmaceuticals, as
well as the importance of surface crystallization for pharmaceutical performance, is …

[HTML][HTML] Amorphous drug-polymer salts

X Yao, AL Neusaenger, L Yu - Pharmaceutics, 2021‏ - mdpi.com
Amorphous formulations provide a general approach to improving the solubility and
bioavailability of drugs. Amorphous medicines for global health should resist crystallization …

Inhibiting surface crystallization and improving dissolution of amorphous loratadine by dextran sulfate nanocoating

A Zeng, X Yao, Y Gui, Y Li, KJ Jones, L Yu - Journal of Pharmaceutical …, 2019‏ - Elsevier
Amorphous formulations provide a solution to poor solubility and slow dissolution of many
drugs, but fast surface crystallization can negate their advantages. As in the case of many …